Connect with us

Technology

Innocan Pharma Submits Investigational New Animal Drug Application to FDA’s Veterinary Center

Published

on

HERZLIYA, Israel and CALGARY, AB, July 26, 2024 /CNW/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA’s Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver and assigned an Investigational New Animal Drug (INAD) number for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product. This represents a significant step for the Company, as an INAD designation facilitates correspondence and data exchange with CVM to support LPT-CBD development as a new veterinary drug.

 

 

The Company further announced that following the assessment of LPT-CBD’s scientific package, the CVM recognized Innocan’s contribution to pursuing innovative animal drug products and technology and granted the company a sponsor fee waiver for fiscal year 2024.  

Innocan’s LPT-CBD is a proprietary drug delivery platform designed to provide prolonged-release CBD for chronic pain and well-being management in animals. Over the past year, repeated administration of LPT-CBD in dogs and other animals has demonstrated both efficacy and tolerability, providing sufficient evidence for the INAD application.

“We are thrilled by CVM’s response,” said Prof. Chezy Barenholz, CSO of Innocan Pharma. “The granted INAD will allow us to advance the investigational studies of LPT-CBD and share knowledge to support future discussions with CVM on LPT-CBD’s development plan. Moreover, the fee waiver, granted by CVM, supports our development and pursuit of innovative animal drug products and technology, further validating our approach and potential impact in veterinary medicine.”

Dr. Eyal Kalo, R&D Director at Innocan, added, “LPT-CBD is a unique technology that has proven itself worthy of the INAD fee waiver granted by CVM. This will streamline our efforts to deliver a unique solution for chronic pain management to the animal market.”

About Innocan Pharma:
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/

Contact Information:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.com 

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/innocan-pharma-submits-investigational-new-animal-drug-application-to-fdas-veterinary-center-302207528.html

SOURCE Innocan Pharma Corporation

Continue Reading

Technology

TECNO Wins Two IFA Global Product Technology Innovation Awards for Modular Phone and Tonino Lamborghini TECNO TAURUS

Published

on

By

BERLIN, Sept. 5, 2026 /PRNewswire/ — TECNO, a global AI-driven innovative technology brand, achieved two IFA Global Product Technology Innovation Awards at IFA 2026:

Tonino Lamborghini TECNO TAURUS took the Miniaturized Gaming PC Technology Innovation Gold Award, standing out with its Italian aesthetics and exceptional performance in the compact body. The TECNO Modular Phone was honored with the Ultra-Slim Magnetic Modular Technology Innovation Gold Award, praised for its ultra-slim craftsmanship and unique modular magnetic technology.

These awards once again demonstrate TECNO’s sustained breakthroughs in product innovation and industry-leading craftsmanship in design excellence. The Global Product Technology Innovation Awards were established in 2014 by IDG, IFA, and DIHK to celebrate excellence across the global consumer electronics industry. The awards honor products that set new industry benchmarks and drive innovation through intelligent technology and user-centric design.

TECNO Modular Phone: The World’s Thinnest Modular Smartphone

At just 4.9mm, the TECNO Modular Phone is powered by proprietary Modular Magnetic Interconnection Technology. It combines a precision magnetic array with pogo-pin connectors, offering a flexible ecosystem for different needs. The host retains a 3000–4000mAh battery, while modules draw power directly for a snap-and-go experience. It also resolves the inherent conflict between rising AI computing demands and limited device space.

The technology has earned over 20 accolades from leading media, with CNET and Yanko Design naming it the Best of MWC 2026, and The Verge recognizing it as the Best Mobile Tech at MWC 2026.

Tonino Lamborghini TECNO TAURUS: One of the World’s Smallest Water-Cooling Gaming Mini-PCs

At around 6.36 liters, the panoramic transparent chassis of the Tonino Lamborghini TECNO TAURUS fuses iconic Italian design with raw engineering. Powered by the Intel® Core™ i9-13900HK and NVIDIA® GeForce RTX™ 5060 (614 AI TOPS, 145W TGP, DLSS 4), it achieves the pinnacle of performance, providing a high-fidelity gaming experience and high-efficiency AI workstation. The water-cooling system sustains peak frequencies, while 15 ports and WiFi 6E deliver connectivity. It was recognized with Yanko Design’s Best of MWC award.

In addition, TECNO made waves at IFA with the Next-Gen Bezelless Concept Phone featuring a revolutionary 0mm screen bezel, and the convertible laptop MEGABOOK T15 360 Pro. Relentlessly pushing the boundaries of design, performance, and AI innovation, TECNO is pioneering limitless possibilities for futuristic technology.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/tecno-wins-two-ifa-global-product-technology-innovation-awards-for-modular-phone-and-tonino-lamborghini-tecno-taurus-302870739.html

Continue Reading

Technology

Morpho UV Printer Unveiled at IFA with Hands-On Live Creation

Published

on

By

BERLIN, Sept. 5, 2026 /PRNewswire/ — Morpho, a company specializing in UV printing technology, is showcasing its first desktop UV printer at IFA 2026, Hall 17-196. Visitors are observing Morpho’s colorful, textured prints, and some have the opportunity to print on a range of blank materials provided.

Morpho’s desktop UV printer can print on a wide range of materials, including wood, glass, leather, metal, and more, delivering vivid colors and tactile textures for customized results. At IFA 2026, the booth attracted interest from creators, educators, and technology professionals, who gathered to watch live demonstrations.

Among those who have tried Morpho’s printer, three aspects are most frequently highlighted: print quality, the moving gantry design, and overall ease of use.

Visitors are first drawn to the prints, which feature precise color reproduction and finely detailed textile textures. With G7 Master ColorSpace certification, Morpho ensures consistent tones across different pieces. The same level of precision is evident in the raised textures created by the industrial-grade printhead, which builds fine layers of ink for detailed, tactile surfaces. The printhead maintains fast carriage motion speeds of up to 600mm/s while preserving precise detail.

Attendees have also noted the printer’s compact desktop footprint. With its moving gantry architecture—where the entire gantry moves along both axes—the printer offers a large, fully enclosed print chamber that accommodates various objects while remaining desktop-friendly.

First-time users have given positive feedback on Morpho’s usability. The integrated Stereo Vision Smart Alignment™ System quickly captures an object’s height and contours, while Morpho Studio’s guided workflows help users move from idea to print with minimal setup.

Morpho’s team shared that the program has been in development for several years, with the goal of making UV printers a practical tool for everyday creative use. Founder Mingyu “Brett” Wang, formerly Global VP of R&D at DJI, commented, “We communicate directly with our community, listen to feedback, and make fast improvements.”

Ahead of IFA, Morpho’s Kickstarter campaign surpassed $10 million in support from over 2,800 backers worldwide. The company is committed to further developing its proprietary core technology and delivering reliable engineering for creators, makers, and small businesses.

Visit Morpho’s website to learn more.

About Morpho: Morpho develops desktop UV printers that bring industrial-grade printing and coloring to everyday materials, enabling creators to turn almost any physical surface into a canvas for their ideas.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/morpho-uv-printer-unveiled-at-ifa-with-hands-on-live-creation-302870741.html

Continue Reading

Technology

Society of Robotic Surgery and Puma Venture Capital Announce Winners of SRS Shark Tank 2026

Published

on

By

Drive Medical claimed the top prize at the third annual SRS Shark Tank 2026, held during the Society of Robotic Surgery’s annual conference at the Diplomat Beach Resort in Hollywood, Florida. The event, a collaboration between SRS and Puma Venture Capital, once again showcased cutting-edge innovations in the digital and robotic surgery ecosystem and featured early-stage companies poised to transform minimally invasive care.

HOLLYWOOD, Fla., Sept. 5, 2026 /PRNewswire-PRWeb/ — Drive Medical claimed the top prize at the third annual SRS Shark Tank 2026, held during the Society of Robotic Surgery’s annual conference at the Diplomat Beach Resort in Hollywood, Florida. The event, a collaboration between SRS and Puma Venture Capital, once again showcased cutting-edge innovations in the digital and robotic surgery ecosystem and featured early-stage companies poised to transform minimally invasive care.

SRS Shark Tank 2026 featured presentations from nine innovative companies. Each had five minutes to pitch their technology and five minutes to engage in a Q&A session with a panel of esteemed judges, including top surgeons, investors, and medical device experts. Companies were evaluated on innovation, impact on healthcare, market potential, business model, and presentation.

Drive Medical earned the top honor for the Pollywog System, the first easy-to-use robotic endoscope integrated with artificial intelligence. The platform is designed to give physicians faster, safer access to the small bowel, allowing diagnosis and treatment to be completed in a single session rather than across multiple procedures.

DeepQure secured second place with HyperQure, the world’s first extravascular renal denervation system for resistant hypertension. Delivered laparoscopically, the device wraps the renal artery from the outside to achieve complete denervation while avoiding the vessel lining.

Microsure came in third with MUSA-3, a microsurgical robot that downscales and stabilizes a surgeon’s hand movements during open super-microsurgical procedures, including free flap, lymphatic, and peripheral nerve surgery. The system received CE mark approval earlier this year.

The strength of the 2026 field extended well beyond the podium: every one of the nine presenting companies was placed in the top three by at least one judge. Reveal Surgical presented optical imaging technology that characterizes tissue for tumor assessment during surgery, and Symphera demonstrated a laparoscopic system that lets surgeons switch instrument tips at the push of a button. Tioga Cardiovascular showed its transcatheter approach to mitral and tricuspid valve replacement.

CardioSentry presented an AI platform for autonomous cardiac ultrasound, and Nina Medical showcased a completely non-invasive treatment for benign prostatic hyperplasia. LITLab rounded out the slate with mobile, high-fidelity surgical training labs that travel to health systems and medtech companies to train clinical teams onsite. Together the group reflected an unusually broad and competitive slate, spanning robotics, imaging, structural heart, urology, and surgical education.

The 2026 judging panel included Steve Bell, Rob Morgan, Dr. Santiago Horgan, Dr. Erik B. Wilson, Scott Zinober, and Babak Tehranchi, and the event was co-chaired by Amit Hazan and Dr. Vipul Patel.

Participating companies included:

Microsure, Symphera, LITLab, Reveal Surgical, DeepQure, Drive Medical, Nina Medical, CardioSentry, and Tioga Cardiovascular.

About the Society of Robotic Surgery:

Founded in 2012, the Society of Robotic Surgery (SRS) is guided by the fundamental principles of education and collaboration as a means to tackle the complex issues of robotic surgery. The SRS’ membership includes more than 20,000 physicians of all disciplines from around the world whose mission is to share information related to multi-centric studies, database collection, fellowship training and funding support related to robotic surgery. The SRS is the only multi-specialty robotic surgery society in the world with an annual meeting that includes updates in more than a dozen medical sub-specialties along with state-of-the-art plenary sessions and hot topic courses.

About Puma Venture Capital:

Puma Venture Capital is an investment firm seeking to leverage its surgeon venture partners to invest in all aspects of physical intelligence across every medical procedure — to improve patient outcomes, lift labor productivity, and lower system costs.

Media Contact

Ryan Julison, Society of Robotic Surgery, 1 3213776877, ryanjulison@gmail.com

View original content:https://www.prweb.com/releases/society-of-robotic-surgery-and-puma-venture-capital-announce-winners-of-srs-shark-tank-2026-302869733.html

SOURCE Society of Robotic Surgery

Continue Reading

Trending